News
We provide the latest news from the world of economics and finance
We provide the latest news from the world of economics and finance
(RTTNews) - Citius Pharmaceuticals, Inc. (CTXR) announced the resubmission of the Biologics License Application or BLA of Lymphir to the FDA on Wednesday.
The resubmission follows concerns raised in the Complete Response Letter received on July 28, 2023.
As per the Center for Drug Evaluation and Research timelines, the FDA is anticipated to provide a Prescription Drug User Fee Act date within 30 days of the resubmission.
Lymphir, also known as denileukin diftitox, is IL-2-based immunotherapy designed for patients with relapsed or refractory cutaneous T-cell lymphoma who have received at least one prior systemic therapy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.
E-mail: 24_support@just2trade.online
